falsefalse

Updates in HER2+ Early and Metastatic Breast Cancer - Episode 14

Emerging Data and Investigational Agents in HER2+ mBC

, , ,

The panel highlights emerging data from SABCS 2022 on investigational agents being explored for HER2+ mBC treatment.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Incidence and Typical Prognosis of HER2+ Early Breast Cancer
    EP. 2: Neoadjuvant Treatment of HER2+ Early Breast Cancer
    EP. 3: De-Escalation Approaches in Patients with HER2+ Early Breast Cancer
    EP. 4: Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer
    EP. 5: Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer
    EP. 6: Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)
    EP. 7: Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer
    EP. 8: Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer
    EP. 9: Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022
    EP. 10: HER2+ mBC: First-Line Treatment Regimens
    EP. 11: Second-Line Treatment of HER2+ mBC and Recent Data Updates
    EP. 12: Options for Third- and Further-Line Treatment of HER2+ mBC
    EP. 13: Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC
    Now Viewing
    EP. 14: Emerging Data and Investigational Agents in HER2+ mBC
    EP. 15: Unmet Needs and the Future of HER2+ Breast Cancer Treatment

    Related Content:

    Updates in HER2+ Early and Metastatic Breast CancerBreast CancerOncLive Peer Exchange®
    OncLive’s FDA Approval Report: The Regulatory Rundown for April 2025
    Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial
    Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL
    x